Ipragliflozin 是一种口服有效的,选择性的SGLT2抑制剂,对人 SGLT2 和 SGLT1,大鼠 SGLT2 和 SGLT1,小鼠 SGLT2 和 SGLT1 的IC50分别为 7.38 和 1876 nM,6.73 和 1166 nM,5.64 和 1380 nM。Ipragliflozin具有抗糖尿病活性。
产品描述
Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
激酶实验
Inhibition of TNF-α synthesis: TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
Cas No.
761423-87-4
分子式
C21H21FO5S
分子量
404.45
别名
ASP1941;伊格列净
储存和溶解度
DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years